文献速递新生儿儿童神经与发育行为

早产儿呼吸暂停新生儿咖啡因治疗11年后的神经行为结局

Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity.
PubMed 文献 · Pediatrics · 2018-04-11

该研究对出生体重500-1250g的早产儿进行11年随访,评估新生儿期咖啡因治疗对神经行为结局的影响。结果显示咖啡因组与安慰剂组神经行为结局总体相似,但咖啡因组在精细运动协调、视运动整合、视觉感知和视空间组织方面表现更好,且一般智力、注意力和行为未受不良影响。

要点

  • 咖啡因组视运动整合、视觉感知和视空间组织均优于安慰剂组。
  • 一般智力、注意力和行为在两组间无不良差异,支持咖啡因长期安全性。

核心结论

  • 新生儿咖啡因治疗呼吸暂停改善了11岁时的视运动、视感知和视空间能力,且未对一般智力、注意力和行为造成不良影响。

研究设计与样本

  • 研究对象为出生体重500-1250g的早产儿,最多870名儿童完成了神经行为评估。
  • 采用回归模型评估咖啡因治疗效应。

主要发现

  • 咖啡因组与安慰剂组神经行为结局总体相似。

临床怎么用

  • 对于出生体重500-1250g的早产儿,新生儿期咖啡因治疗呼吸暂停与11岁时视运动、视感知和视空间能力改善相关。
  • 咖啡因治疗未显示对一般智力、注意力和行为的不良影响,支持其长期安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Caffeine is effective in the treatment of apnea of prematurity. Although caffeine therapy has a benefit on gross motor skills in school-aged children, effects on neurobehavioral outcomes are not fully understood. We aimed to investigate effects of neonatal caffeine therapy in very low birth weight (500-1250 g) infants on neurobehavioral outcomes in 11-year-old participants of the Caffeine for Apnea of Prematurity trial. METHODS: Thirteen academic hospitals in Canada, Australia, Great Britain, and Sweden participated in this part of the 11-year follow-up of the double-blind, randomized, placebo-controlled trial. Measures of general intelligence, attention, executive function, visuomotor integration and perception, and behavior were obtained in up to 870 children. The effects of caffeine therapy were assessed by using regression models. RESULTS: Neurobehavioral outcomes were generally similar for both the caffeine and placebo group. The caffeine group performed better than the placebo group in fine motor coordination (mean difference [MD] = 2.9; 95% confidence interval [CI]: 0.7 to 5.1; P = .01), visuomotor integration (MD = 1.8; 95% CI: 0.0 to 3.7; P < .05), visual perception (MD = 2.0; 95% CI: 0.3 to 3.8; P = .02), and visuospatial organization (MD = 1.2; 95% CI: 0.4 to 2.0; P = .003). CONCLUSIONS: Neonatal caffeine therapy for apnea of prematurity improved visuomotor, visuoperceptual, and visuospatial abilities at age 11 years. General intelligence, attention, and behavior were not adversely affected by caffeine, which highlights the long-term safety of caffeine therapy for apnea of prematurity in very low birth weight neonates.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Mürner-Lavanchy IM, Doyle LW, Schmidt B, et al. Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. Pediatrics. 2018. PMID: 29643070. doi:10.1542/peds.2017-4047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。